Ledger.Open graph →
SEC Form D · filed January 2, 2020

Summit Therapeutics plc

Offering
$47.4M
Sold
$47.4M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
ABINGDON, United Kingdom
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (16)

David Roblin · Abingdon, United KingdomExecGlyn Edwards · Abingdon, United KingdomExec · DirectorRobert W. Duggan · Abingdon, United KingdomDirectorManmeet W. Soni · Abingdon, United KingdomDirectorValeska Schroeder · MENLO PARK, CAExecStaffan Encrantz · MENLO PARK, CAExec · DirectorElaine W. Stracker · Abingdon, United KingdomDirectorDaniel W. Elger · Abingdon, United KingdomExecVentzislav W. Stefanov · Abingdon, United KingdomDirectorFred H. Deserio · NEW YORK, NYExecSaurabh Bhansali · Chicago, ILExec · DirectorRobert W. Duggan · Abingdon, United KingdomDirectorElaine W. Stracker · Abingdon, United KingdomDirectorManmeet W. Soni · Abingdon, United KingdomDirectorDaniel W. Elger · Abingdon, United KingdomExecVentzislav W. Stefanov · Abingdon, United KingdomDirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗